Status:
COMPLETED
ADASUVE 2-dose Thorough QT/QTc Study
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Assess the potential effects on the QT interval of 2 consecutive doses of ADASUVE administered 2 hours apart, in relation to placebo and an active control in healthy volunteers.
Detailed Description
It has been shown in a pre-marketing clinical study that clinically relevant QT prolongation does not appear to be associated with a single dose of ADASUVE. The potential risk of QTc prolongation foll...
Eligibility Criteria
Inclusion
- Male and female subjects between the ages of 18 to 65 years, inclusive.
- Body mass index (BMI) ≥18 and ≤32.
- Subjects who are willing and able to comply with the study schedule and requirements, and stay at the CRU for a 4-day period and 2 consecutive 3-day periods.
- Subjects who speak, read, and understand English and/or Dutch and are willing and able to provide written informed consent on an IEC approved form prior to the initiation of any study procedures.
- Subjects who are in good general health prior to study participation
- Female or male participants who agree to use a medically acceptable and effective birth control method
Exclusion
- Subjects who regularly consume large amounts of xanthine-containing substances (≥ 5 cups of coffee/day).
- Subjects who have taken prescription or nonprescription medication within 5 days of Visit 2.
- Subjects who have had an acute illness within the last 5 days of Visit 2.
- Subjects who have smoked tobacco within the last 30 days or who have a positive cotinine test.
- Subjects who have a history of HIV, anti-HCV or HbsAg positivity.
- Subjects who have a history within the past 2 years of drug or alcohol dependence or abuse as defined by DSM-IV.
- Subjects who test positive for alcohol or have a positive urine drug screen.
- Subjects who have a history of allergy or intolerance to loxapine or amoxapine or history of bronchospasm following inhaled loxapine treatment.
- Subjects who have an ECG abnormality.
- Subjects who have hypotension, or hypertension.
- Subjects who have a history of unstable angina, syncope, coronary artery disease, myocardial infarction, congestive heart failure, transient ischemic attack, history of convulsions or other neurological disorder.
- Subjects who have a current history of asthma, chronic obstructive lung disease, or any other lung disease associated with bronchospasm.
- Subjects who use medications to treat airways disease, such as asthma or COPD.
- Subjects who have any acute respiratory signs/symptoms (e.g., wheezing).
- Female subjects who have a positive pregnancy test at screening or at admission to any of the treatment visits, or are breastfeeding.
- Subjects who have received an investigational drug within 60 days prior to the Screening Visit.
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2013
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01854710
Start Date
May 1 2013
End Date
July 1 2013
Last Update
October 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRA International
Zuidlaren, Netherlands